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Background: Among the essential biological roles of bone marrow-derived cells, secretion of many soluble
factors is included and these small molecules can act upon specific receptors present in many tissues including
the nervous system. Some of the released molecules can induce proliferation of Schwann cells (SC), satellite cells
and lumbar spinal cord astrocytes during early steps of regeneration in a rat model of sciatic nerve transection.
These are the major glial cell types that support neuronal survival and axonal growth following peripheral nerve
injury. Fibroblast growth factor-2 (FGF-2) is the main mitogenic factor for SCs and is released in large amounts by
bone marrow-derived cells, as well as by growing axons and endoneurial fibroblasts during development and
regeneration of the peripheral nervous system (PNS).
Results: Here we show that bone marrow-derived cell treatment induce an increase in the expression of FGF-2 in
the sciatic nerve, dorsal root ganglia and the dorsolateral (DL) region of the lumbar spinal cord (LSC) in a model of
sciatic nerve transection and connection into a hollow tube. SCs in culture in the presence of bone marrow derived
conditioned media (CM) resulted in increased proliferation and migration. This effect was reduced when FGF-2 was
neutralized by pretreating BMMC or CM with a specific antibody. The increased expression of FGF-2 was validated
by RT-PCR and immunocytochemistry in co-cultures of bone marrow derived cells with sciatic nerve explants and
regenerating nerve tissue respectivelly.
Conclusion: We conclude that FGF-2 secreted by BMMC strongly increases early glial proliferation, which can
potentially improve PNS regeneration.
Keywords: Regeneration, Sciatic nerve, Dorsal root ganglia, Spinal cord, FGF-2, Schwann cell, Bone marrow
derived cells, ProliferationBackground
Although peripheral nerves have the ability to regenerate
their axons after total transection, full functionality is usu-
ally not recovered. Molecular and cellular events that occur
during early steps of nerve regeneration include axonal
fragmentation and phagocytosis by invading macrophages* Correspondence: vtulio@biof.ufrj.br
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distribution, and reproduction in any medium[1]. Schwann cells (SCs) sort axons by inserting cytoplas-
mic protrusions into axonal bundles and ensheathing
them [2]. In the absence of contact axons, SCs assume a
non-myelinating phenotype and proliferate, migrate and
form structures called bands of Büngner [2-4]. Non-
myelinating SCs also behave similarly to support axons
to grow toward the original target tissue. This sequence
of events following axonal injury is known as Wallerian
degeneration [1]. SCs and satellite cells that ensheathe
sensory neurons in the dorsal root ganglia (DRG) prolif-
erate and release soluble factors when peripheral somatic
nerves are injured [5]. This increases the number of
satellite cells that support neuronal survival during PNS
regeneration [6-9]. Basic fibroblast growth factor (FGF-2)Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cell proliferation by binding to the FGF-2 receptor type
1/2 (FGFR 1/2) during both development and regener-
ation of PNS [10]. Overexpression of FGF-2 at a sciatic
nerve lesion site in genetically modified adult mice
increased SCs proliferation and reduced SC myelinating
phenotype [11]. In addition, it has been shown that
axotomy-induced loss of sensory neurons resulted in
increased neuronal apoptosis and reduced neuritogenesis
in vitro in the absence of FGFR type 3 (FGFR-3) com-
pared to the wild-type mice [12]. Application of SCs
overexpressing the 21/23-kDa isoforms of FGF-2 into long
gaps (> 1 cm) of transected sciatic nerve resulted in
higher numbers of regenerated axonal fibers and myelin-
ated fibers [13]. Moreover, SCs overexpressing FGF-2
combined with embryonic tissue containing dopaminergic
neurons and grafted into the striatum of a mouse model
of Parkinson’s disease led to functional recovery [14].
It was also recently demonstrated an increase in the
expression of FGF-2 in axons of retinal ganglion cells
treated with bone marrow mononuclear cells in a model
of optic nerve crush [15] and this increase was correlated
with a larger number of regenerating axons [15]. In other
tissues such as heart it has been shown that soluble factors
derived from bone marrow derived mesenchymal cells res-
cue cardiomiocytes from necrosis in vitro and were able to
promote recovery of basic parameters of cardiac function
in vivo [16]. We have previously observed that trophic
activity stimulated by bone marrow derived cells strongly
increases proliferation of SCs, satellite cells, and astrocytes
surrounding lumbar spinal cord motoneurons [5]. Here,
we tested the possibility that bone marrow cells act by
delivering FGF-2 to the gap between the proximal and dis-
tal stumps of transected sciatic nerve. Our data show that
the increase in cell proliferation induced by bone marrow
derived cells can be blocked by the administration of an
FGF-2 neutralizing antibody both in vivo and in vitro.
Using RT-PCR, we observed that the levels of FGF-2
mRNA expressed by bone marrow derived mesenchymal
cells (MSC) increase when these cells are co-cultured with
sciatic nerve fragments. In addition, the presence of bone
marrow derived cells in the injury site induces an increase
in the expression of FGF-2 in SCs, DRG satellite cells and
lumbar spinal astrocytes when compared with the control
untreated animals. We suggest that the both the FGF-2
released by the bone marrow derived cells and the
increased expression in the resident cells of the nervous
system results in an increase in glial cells proliferation and
may contribute to an improvement in regeneration.
Materials and methods
Animals
We used 3-month-old male Lister Hooded rats (n = 25)
bred at our institution’s rodent facility and housed withfree access to food and water. All experiments were per-
formed following the National Institute of Health Guide-
lines for the Care and Use of Laboratory Animals and
approved by the Committee for the Use of Experimental
Animals from the Universidade Federal do Rio de
Janeiro (CEUA protocol # 064).
To obtain bone marrow cells, rats were deeply
anesthetized with ether and sacrificed by cervical dis-
location. The tibia and femur were removed and
cleaned of muscles, and the epiphyses were cut. Bone
marrow was flushed from the bones using 15 mL of
DMEM F-12 (Dulbecco’s Modified Eagle Medium), and
the collected cells were gently dissociated with a Pas-
teur pipette. The mononuclear fraction was separated
using Histopaque 1083, (Sigma-Aldrich, St. Louis, MO,
USA), after centrifugation at 260 × g for 25 min at
room temperature. The mononuclear fraction layer was
carefully removed, and the cells were washed 3 times
with DMEM F-12. After the last wash, cells were
counted and tested for viability with trypan blue (Invi-
trogen, Carlsbad, CA, USA).Surgical procedures
Total transection and connection of the sciatic nerve
(SN) was performed under anesthesia with xylazine
chloride (5 g/Kg Rumpum 0.5%, Bayer, São Paulo, Brazil)
and ketamine chloride (50 g/Kg Vetaset 5%, Fort Dodge
Laboratories, São Paulo, Brazil). The right sciatic nerves
were exposed and sectioned at the mid thigh level. Distal
and proximal stumps were re-connected inside an 8-mm
polyethylene tube, leaving a gap of 4 mm between both
stumps inside the tube. One group of rats received 1.2 ×
107 cells in 15 μL of a Matrigel solution (30% Matrigel
in 10 mM phosphate buffer (PBS), Collaborative Bio-
medical Products, Bedford, MA, USA) (BMMC group;
n = 6; Figure 1B). Cell injections were performed with a
10-μL microsyringe immediately after the surgery and
reconnection (Hamilton, Reno, NV, USA). The control
group received only the matrigel solution (PBS group;
n = 5; Figure 1A). For the experiments with the neutral-
izing antibody an osmotic pump system (ALZET mini
pumps, Cupertino, CA, USA) was used to deliver the
neutralizing FGF-2 antibody to the tube. This group
(n = 4, Figure 2C) received first the same number of cells
followed immediately by a plugged needle on top of the
tube that delivered antibody continuously into the gap
containing BMMC. Osmotic pumps were filled up with
200 μL of solution containing 100 μg/mL of neutralizing
mouse monoclonal α-FGF-2 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). The delivery rate was 0.5 μL/h.
After recovery from anesthesia, the animals were
returned to the animal facility and kept with food and
water ad libitum for 10 days.
Figure 1 Illustration of in vivo experimental model of rat sciatic nerve. A-C: Full transection of sciatic nerve followed by connection of
proximal and distal stumps inside a hollow tube of silicon and treatment with PBS (A), bone marrow mononuclear cells (BMMC) (B), or
BMMC+neutralizing FGF-2 antibody delivered inside the gap by a cannula coupled to an osmotic mini-pump (C).
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Rats were deeply anesthetized in the CO2 chamber and
perfused with paraformaldehyde 4% (PF 4% in 0.1 M
PBS, pH 7.4) to examine the role of FGF2 on glial cell
proliferation ten days after surgical procedures. The
sciatic nerve (SN), DRG (L5) and lumbar spinal cord
(LSC) were removed and kept in a 30% sucrose solu-
tion in 0.1 M PBS, pH 7.4 for 48 h. Tissue samples
were mounted in optimal cutting temperature (OCT)
compound (Sakura Fine Technologies, Zoeterwoude,
Netherlands). Frozen longitudinal sections (16 μm) of
SN and DRG and transverse sections of LSC (16 μm)
were cut on a cryostat (Leica CM 1850, Wetzlar,
Germany) and mounted directly onto gelatin pre-coated
slides. DRG and LSC sample sections were stained with
neutral red (1% neutral red in 0.1 M acetate buffer,
pH 4.8). These sections were dehydrated, mounted with
Enthelan (Merck, Rio de Janeiro, Brazil) and analyzed
on an Axiovert 135 microscope equipped with an
Axiocam (Zeiss, Aktiengesellschaft, Germany). Another
group of slices was stored at −20°C for immunofluores-
cence procedures.Culture of bone marrow-derived mesenchymal cells
After harvest (described above), bone marrow cells were
plated in DMEM F-12 with 10% fetal bovine serum
(FBS, Invitrogen), penicillin and streptomycin (10,000
units/mL and 10 mg/mL respectively, Sigma), fungizone
(10 mg/mL, Sigma), glutamine (100 mg/mL, Invitrogen)
and sucrose (0.15%, Sigma). Cells (2 × 105) were added
to 10-cm dishes (Corning, Corning, NY, USA) and kept
in the incubator with 5% CO2 overnight at 37°C. Non-
adherent cells were removed and adhered cells were
supplemented with fresh DMEM F-12 + 10% fetal bovine
serum (FBS) after 24 h in culture. Confluent cells in
passage number 3 were kept in culture for 72 h with
standard media (DMEM F-12 + 10% FBS). Then, BMMC
conditioned medium (BMMC-CM) was collected, centri-
fuged at 260 × g for 10 min, filtered with a 0.22 μm filter
and frozen at −20°C.
Schwann cells and in vitro proliferation assay
The ST-8814 human lineage of SCs was cultured with
DMEM F12 + 10% FBS, until 70% confluent in 24-well
culture dish (Corning). Cells were then re-plated and
Ribeiro-Resende et al. Molecular Neurodegeneration 2012, 7:34 Page 4 of 17
http://www.molecularneurodegeneration.com/content/7/1/34incubated with CM diluted 1:1 with standard medium
after 3 passages. Another group of cells was incubated
with CM+neutralizing mAb anti-FGF-2 (1:1000). Re-
combinant human FGF-2 (rhFGF-2, Invitrogen) was also
added as a positive control, as well as the same recom-
binant protein in the presence of the neutralizing mAb
as a control for neutralization. The control group of
cells was kept with DMEM F-12 + 10% FBS. All groups
were then incubated for 72 h in 5% CO2 at 37°C. After
that, cells were washed once with 10 mM PBS, pH 7.4
and fixed with paraformaldehyde 4% (PF 4%) in PBS, pH
7.4. To investigate the proliferative effect of CM on cul-
tured SCs, we performed immunostaining for KI-67, a
marker of proliferation. Fixed Schwann cells were
washed 3 times for 5 min each with 10 mM PBS,
pH 7.4, followed by incubation with 5% normal goat
serum (NGS) for 30 min and KI-67 IgG rabbit poly-
clonal antibody (1:200, Abcam, Cambridge, MA, USA)
overnight. Afterwards, cells were washed again 3 times
with 10 mM PBS for 5 min and mounted with coverslips
containing one drop of Vectashield with 4’, 6’-diamidino-
2-phenylindole (DAPI, Vector, Burlingame, CA, USA)
for nuclei counterstaining. KI-67+ Schwann cells were
counted and compared among the different experi-
mental conditions.
DRG explants and in vitro neurite growth assay
DRG explant cultures were obtained from E16 rat
embryos. Pregnant rats were sacrificed by cervical dis-
location, and the embryos were removed immediately.
DRGs were dissected and incubated in DMEM F-12 with
50 ng/mL NGF (Invitrogen) for 1 h at 36°C and 5% CO2
before plating on coverslips pre-coated with 100 μg/mL
of poly-L-lysine (Sigma) and 50 μg/mL of laminin (Invi-
trogen). DRGs explants were plated in 6 experimental
groups. The control group was cultured with DMEM F-
12 (n = 5). A second group was kept with CM diluted 1:1
with standard medium (DMEM F-12 + 10% FBS, n = 5).
A third group had CM+neutralizing FGF-2 antibody
(2.5 μg/mL, Abcam). A fourth group had recombinant
human FGF-2 protein (rhFGF-2, 20 ng/mL, Invitrogen)
added to the standard medium. The fifth group received
rhFGF-2 + neutralizing antibody for FGF-2 (same con-
centration as described above) and the last group
received rhFGF-2 and rhNGF (20 ng/mL both, Invitro-
gen) . DRG explants were incubated for 48 h and then
washed once with 10 mM PBS, fixed with PF 4% and
double immunostained with antibodies against Tuj-1
(1:500, Covance, Princeton, NJ, USA) and glial fibrillary
acidic protein (GFAP, 1:400, DAKO, São Paulo, Brazil)
following the same procedures as described above for
cultured SCs. Cell nuclei were counterstained with
DAPI-containing Vectashield. Neurite growth was
assessed by confocal microscopy (LSM 510 Meta, Zeiss).The number of neurites from the DRG neurons was
counted and compared among all experimental conditions.
Dissociated DRG neurons in vitro
DRG explants were obtained from E14 rat embryos as
described above. DRGs were dissected and incubated in
DMEM F-12 with 50 ng/mL NGF (Invitrogen) for 1 h at
36°C in 5% CO2. Ganglia were cleaned and incubated at
37°C with 0.05% trypsin for 10 min in Ca2+ and Mg2+
Free Hanks’ solution (CMF). After centrifugation and
removal of the trypsin solution, the ganglia were washed
with 10 mL of DMEM and 10% FBS, and triturated with
a fire-polished Pasteur pipette. Neurons and glial cells
were plated at a low density on poly-L-lysine- (10 μg/ml)
and laminin- (20 μg/ml) coated 4-well dishes (Nunc
Inc., Rochester, NY, USA) [17]. Culture conditions were
the same as described above for DRG explants. The neu-
rons were incubated at 37°C in a humidified 5% CO2 in-
cubator for 48 h. At least three independent counts were
repeated for each experimental paradigm. Neurite
growth was assessed with confocal microscopy after
double immunostaining for Tuj-1 and GFAP.
Sciatic nerve explants and SC migration assay
Two rats had both sciatic nerves crushed at the mid-
thigh level under anesthesia as described above. After
24 h these animals were sacrificed by cervical contusion,
and the nerves were carefully removed. The aim of this
procedure was to activate Schwann cells at distal stump
after lesion since axons were disrupted. Then, the
epineurium tissue from the distal nerve stumps was
removed under low magnification microscopy, and
small pieces of nerve (explants) were removed with oph-
thalmic scissors. One explant per well was placed in a
24-well culture dish containing coverslips pre-coated
with 100 μg/mL of poly-D-lysine (Sigma) and 50 μg/mL
of laminin (Invitrogen). Explants were kept at 37°C, 5%
CO2 for 5 days with DMEM F-12 + 20% FBS, and 5 days
more under the same experimental conditions as
described above for cultured Schwann cells. Then, the
cultures were fixed with 4% PF for 15 min, washed
3 times for 5 min each with 10 mM PBS, pH 7.4 and
immunostained for S100-β (1:400, rabbit polyclonal,
DAKO). Anti-rabbit IgG Alexa 555 (Invitrogen, 1:800)
was applied as secondary antibody. Cell nuclei were
counterstained with DAPI-containing Vectashield. Fluor-
escence was imaged by an Apotome system (Zeiss,
Germany) coupled to a microscope (Axiovert 200 M,
Zeiss, Germany) and captured by a camera (Axiocam,
Zeiss). The number of S100-β+Schwann cells that
migrated from the nerve explants were counted in a
fixed area represented by the dashed square in
Figure 3A and compared among all experimental condi-
tions. The total number of cells that migrated (DAPI+)
Figure 2 Increased expression of FGF-2 is time correlated with increased Schwann cell proliferation in the sciatic nerve after lesion and
BMMC treatment. A-E: Optical sections of sciatic nerve by confocal microscopy taken 10 days after total transection immunolabeled for FGF-2
and treated with PBS (A, proximal stump and B, distal stump) or with BMMC (C, proximal stump and D, distal stump). An intact nerve is showed
in E. Cell nuclei were counterstained with TO-PRO. F: Histogram of FGF-2 expression in sciatic nerve tissue comparing different experimental
groups. Statistics: p< 0.0001 ANOVA. G-M: Optical sections of sciatic nerve by confocal microscopy taken 10 days after total transection double
immunolabeled for KI-67 (red) and GFAP (green) treated with PBS (G, proximal stump and J, distal stump), with BMMC (H, proximal stump and K,
distal stump) or BMMC+neutralizing antibody for FGF-2 (I, proximal stump and L, distal stump) delivered by osmotic mini-pumps. Uninjured
nerve is showed in M. N: Histogram of the number of KI-67+ SCs in the nerve tissue under the different experimental conditions. Statistics:
p< 0.001 ANOVA. Scale bar: A-E; G-M= 50 μm.
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parameters.slices by confocal microscopy of longitudinal
sections of DRG double immunolabeled for KI-67 (red),
GFAP (green) and counterstained with TO-PRO (blue)
ten days after sciatic nerve lesion treated with PBS (G),
BMMC (H), BMMC+neutralizing FGF-2 antibody (I)
delivered by osmotic mimi-pumps or uninjured sciatic
nerve (F). J: Quantification of the number of KI-67+
cells per mm2 of DRG tissue comparing the experi-
mental groups. Statistics: p< 0.0001 ANOVA. Scale bar:
A= 200 μm; B-D, F-I= 50 μm.
Immunofluorescence procedures
For double immunostaining with KI-67 and GFAP, fro-
zen sections were equilibrated to room temperature
(RT) inside a humid chamber. The slides were then
placed in a 4% PF wet chamber for 30 min to promote
adhesion of the sections to the slides. Next, slides were
washed twice for 5 min each with 10 mM PBS, pH 7.4
at RT prior to 30 min incubation in 0.01 M citrate buf-
fer, pH 6.0 at 95°C. Then, slides were washed three times
with 10 mM PBS, pH 7.4 + 0.3% Triton X-100. After
these procedures, slides were incubated with 5% normal
goat serum (NGS, Invitrogen) in wash solution for 1 h at
RT. Incubation with the primary antibodies KI-67 rabbit
monoclonal (1:50, Abcam) and GFAP mouse monoclo-
nal (1:400, Dako) was performed overnight at 4°C fol-
lowed by 3 washes with 10 mM PBS+ 0.3% Triton X-
100 (5 min each) and then sections were incubated with
appropriate secondary antibodies Alexa Fluor 488-
conjugated goat anti-mouse (1:400, Invitrogen) and Cy3
goat anti-rabbit (1:400, Jackson Laboratories, Bar Har-
bor, ME, USA) for 2 h at room temperature. After 3
washes, sections were mounted with Vectashield with
DAPI (Vector) and analyzed with an epifluorescent
microscope (Axiovert 200 M, Zeiss) or confocal micro-
scope (LSM 510 META, Zeiss). Neurons co-cultured
with SCs were also fixed with paraformaldehyde 4%,
washed 3 times with 10 mM PBS+ 0.1% triton, incu-
bated with 5% NGS for 1 h followed by incubation with
monoclonal anti-mouse Tuj-1 (1:500, Covance) for 2 h.
Cells were again washed 3 times with 10 mM PBS and
incubated with anti-mouse Cy3 (1:400, Jackson labora-
tories). Again, neurite outgrowth was assessed with con-
focal microscopy (LSM 510, Zeiss).
Western blotting
For western blotting assay, SCs were incubated under
different experimental conditions as described above,
with medium containing 0.1% FBS for 22 h followed by
2 h of culture serum withdrawal. After, SCs were washed
twice with cold 10 mM PBS, pH 7.4 containing Ca2+.
RIPA buffer complemented with 1 mM sodium orthova-
nadate and 1 mM sodium fluoride was added to theplates to lyse cells, and the mixture was incubated for
20 min at 4°C, followed by DNA shearing. Samples were
then treated with sample buffer and resolved by 15%
SDS-PAGE gels, and then transferred to nitrocellulose
membranes. After blocking with TBS+ 3% BSA for 2 h
at room temperature, membranes were incubated with
anti-phospho Erk 1/2 (1:2000, rabbit polyclonal, Cell Sig-
naling, Danvers, MA, USA), anti-phospho Akt 1/2/3
(1:1000, rabbit polyclonal, Santa Cruz Biotechnology,
Santa Cruz, CA, US), or anti-Erk (1:1000, rabbit poly-
clonal, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and anti-Akt 1/2/3 (1:1000, rabbit polyclonal Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 2 h at room
temperature. Protein bands were visualized by incu-
bation with goat anti-rabbit horseradish peroxidase-
conjugated antibody (1:40.000, Bio-Rad Laboratories,
CA, USA) and ECL Western blot analysis system (Amer-
sham Pharmacia Biotech, Piscataway, NJ, USA). Images
were scanned and intensity analysis was carried out
using Image J software.Reverse transcription polymerase chain reaction
(RT-PCR)
Total RNA was extracted from BMMC or MSC incu-
bated with or without sciatic nerve fragments using TRI-
zol reagent (Invitrogen). Total RNA (2 μg per sample)
was treated with amplification-grade DNAse I (Invitro-
gen) and reverse-transcribed with Superscript II Reverse
Transcriptase (Invitrogen) and OligodT18 (IDT, Coral-
ville, IA, USA). PCR reactions were performed with
PlatinumW Taq DNA Polymerase (Invitrogen). RNA extrac-
tion, cDNA synthesis, and PCR reactions were per-
formed according to the manufacturers’ instructions.
FGF-2 and GAPDH were amplified using a melting
temperature of 60°C. PCR products were analyzed by
electrophoresis on 1.5% agarose gels stained with eth-
idium bromide. GAPDH was used as an internal amplifi-
cation control. The following primer sequences were
used: FGF-2 5-AGGAAGATGGACGGCTGCTG (forward)
and 5-GCCCAGTTCGTTTCAGTGCC (reverse); GAPDH
5-ATCAAGAAGGTGGTGAAGCAGG (forward) and 5-
AGGTGGAAGAGTGGGAGTTGCT (reverse).Quantitative analyses and statistics
KI-67/GFAP+ cells were counted in optical sections
obtained by confocal microscope (LSM 510 Meta,
Zeiss, Germany). Longitudinal sections of SN (n = 14)
and DRG L4/L5 (n = 14) and transversal sections from
lumbar spinal cord (n = 14) were analyzed after immu-
nostaining, as described above. In vitro neurite exten-
sion from the DRG neurons was assessed from images
using Axiovision 4.3 software (Carl Zeiss, Germany).
The same software was also employed to count the
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sciatic nerve explants.
Statistical analyses were performed using one way ana-
lysis of variance (ANOVA) followed by a Neuman-Keuls
post-test comparing all pairs of columns. All data are
expressed as mean± standard error of the mean (SEM).
Symbols in the histograms: * p< 0,01; ** p< 0,001 and
*** p< 0,0001.
Results
Expression of FGF-2 in regenerating nerves and increased
glial proliferation after BMMC treatment
Figure 1 illustrates the experimental design for injection of
bone marrow derived cells (~2,5x107, Figure 1B), vehicle
(PBS, Figure 1A) or neutralizing anti-FGF-2 antibody
(Figure 1C) into a polyethylene tube reconnecting both
stumps (4 mm gap) after sciatic nerve transection of 3-
month-old Lister Hooded male rats. Immunofluorescent
labeling of longitudinal sections of the sciatic nerve
(Figure 2A-E) shows that FGF-2 expression is increased at
the proximal stump in rats that received bone marrow cells
(Figure 2C) compared to the vehicle group (Figure 2A)
10 days after injury (DAI). On the other hand, FGF-2
expression had basal levels on unlesioned control rats
(Figure 2E). Colocalization of FGF-2 and Erb-B2 receptor
is found on the surface of SCs (Additional file 1:
Figure S1). The quantitative analysis among the experi-
mental groups is shown in Figure 2F. Since an increased
expression of FGF-2 is correlated with cell proliferation in
the regenerating nerve tissue, the number of KI-67/GFAP+
SC nuclei was evaluated at the proximal stump. As shown,
it was found to be significantly increased in the treated
group as compared to theother groups (Figure 2G, H, N).
This proliferation is concurrent with the increase in FGF-2
expression in the regenerating proximal stump. The
expression of FGF-2 in both experimental conditions was
higher at the distal stump compared to the proximal stump
(Figure 2B, D, F). However, there were no differences in ei-
ther FGF-2 expression or SC proliferation between BMMC
and PBS groups in the distal stump (Figure 2J, K, N). The
same is true for SC proliferation; the number of KI-67/
GFAP+SC was increased at the proximal stump of nerves
treated with cells when compared with the other groups
(Figure 2H, N). Addition of the neutralizing FGF-2 anti-
body in rats that received cells decreased the expression
levels of FGF-2 (data not shown) and also SC proliferation
in the regenerating nerve tissue compared to the vehicle
group in both the proximal and distal stumps (Figure 2I,
L, N). Control rats with unlesioned nerves had low levels
of expression of FGF-2 and KI-67 (Figure 2E, F, M, N). To
address whether FGF-2 is expressed by axons, Schwann
cells or both we double immunolabeled longitudinal sec-
tion of cell treated sciatic nerves at the proximal stump
with anti-GFAP and anti-FGF-2 antibodies (Figure 4A) orwith ant-NF-200 and anti-FGF-2 antibodies (Figure 4B).
We found co-localisation of FGF-2 with GFAP and also
with NF-200 suggesting that FGF-2 is present in both SC
and axons in the regenerating nerve tissue.
Increased expression of FGF-2 in the dorsal root ganglia
(DRG) after cell treatment
Expression of FGF-2 was investigated in DRGs with dis-
rupted sensory fibers growing their axons toward the sci-
atic nerve together with axons of motoneurons present in
the L5 LSC. A representative low-magnification image of
longitudinal sections of L5 DRGs in a control rat stained
with neutral red is shown in Figure 5A. Also, an insert is
shown for large, medium and small sensory neurons.
Immunofluorescently labeled cells for FGF-2 is shown at
basal levels staining in PBS-treated transected nerves at
ten DAI (Control group, Figure 5B, C, E). Transplantation
of bone marrow-derived cells into the injury site signifi-
cantly increased the expression of FGF-2 compared to the
vehicle group (Figure 5D, E). Double immunolabeling for
KI-67 and GFAP in serial sections indicate the basal pro-
liferation rate of satellite cells in uninjured group
(Figure 5F, J), but upon injury, a ~5-fold increase is
observed in the number of KI-67+ satellite cells
(Figure 5H, J). Cells treatment increased the number of
KI-67+ satellite cells 2- and 15-fold compared to the ve-
hicle and uninjured groups, respectively (Figure 5H, J).
Delivery of neutralizing FGF-2 antibody in the cell
treated groupreduced the number of KI-67+ satellite cells
approximately 7-fold compared to the cell-only group
(Figure 5I-J). To address whether FGF-2 is expressed by
DRG neurons, satellite cells or both, we immunostained
longitudinal section of DRG of rats treated with cells with
anti-GFAP and anti-FGF-2 antibodies (Figure 4C) or with
anti-NF-200 and anti-FGF-2 antibodies (Figure 4D). We
observed a strong co-localisation of FGF-2 with GFAP
but almost none with NF-200 indicating that FGF-2 is
mainly expressed by satellite cells but not by the neurons
in the DRGs. There were few dots of co-localization of
FGF-2 and NF-200. FGF-2 which are probably axons in
the vicinity of the cell bodies (Figure 4D arrows). These
data suggest that the observed overexpression of FGF-2
in the DRG tissue is induced by treatment with bone
marrow-derived cells and subsequent increased satellite
cell proliferation.
Expression of FGF-2 and astrocyte proliferation in the LSC
after cell treatment
FGF-2 is not detected in uninjured motoneuron cell bodies
or axons in sciatic nerve at DL area of the anterior horn in
the LSC (Figure 6A, D, G). However, FGF-2 expression by
glial and neuronal cells is significantly increased at the ipsi-
lateral, but not the contralateral, side of the LSC 10 DAI
(Figure 6B, C, G). Injection of bone marrow-derived cells
Figure 3 FGF-2 secreted by BMMC increases SC migration from sciatic nerve explants. A-F: Crushed sciatic nerve explants from distal
nerve stump kept for ten days in culture under specific experimental conditions. A: Phase contrast image showing one explant with cells
migrating from the tissue. B-F: Epifluorescent microscopy of migrating SCs immunolabeled for S-100β (green) and incubated with control
medium (A), BMMC-CM (B), BMMC-CM+ neutralizing FGF-2 (C), rhFGF-2 added to the control medium (D) or rhFGF-2 + neutralizing FGF-2 (E).
Cell nuclei were counterstained with DAPI. F: Quantitative analysis of the number of S-100β migrated SCs from sciatic nerve explants after
incubation under different experimental conditions. Statistics: p<0.0001 ANOVA. Non-Schwann cells are indicated by thick or thin arrows in B.
Scale bar: A-F= 50 μm.
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contralateral sides compared to the uninjured or vehicle
(PBS) groups (Figure 6E, F, G, p< 0.001). Both motoneur-
ons and glial cells showed an increase in FGF-2 following
cell treatment (Figure 6E). To investigate whether this in-
crease was also associated with an increase in astrocyte
proliferation, spinal cord sections were double labeled
with GFAP and KI-67. In the uninjured group, very few
cells were positive for both markers (Figure 6N-O), but
these numbers increased on the ipsilateral side of the PBS
group 10 DAI. Expression of GFAP and KI-67 proliferat-
ing astrocytes were similar to the uninjured group on the
contralateral side (Figure 6H, K, O; Additional file 2:Figure S2). The treatment of BMMCs increased the num-
ber of KI-67+ astrocytes but not GFAP reactivity at the
ipsilateral side compared to the PBS group 10 DAI.
Expression of both markers was similar to the uninjured
group on the contralateral side (Figure 6I, L, O)
(Additional file 2: Figure S2). Delivery of BMMC in the
presence of neutralizing FGF-2 antibody reduced the
number of KI-67+ astrocytes (from 43.43 ± 6.21 to
26.22 ± 5.57 proliferating astrocytes per mm2; p< 0.001).
However, this condition also had an increase in GFAP
reactivity (p< 0.01 ANOVA) compared to the vehicle
group. (Figure 6J, M, O; Additional file 2: Figure S2). To
address whether FGF-2 is expressed by motoneurons,
Figure 4 Localization of FGF-2 in the regenerating nerve tissue, DRG and lumbar spinal cord. A-H: Optical slices by confocal microscopy
of longitudinal sections of sciatic nerve at proximal stump (A and B) or dorsal root ganglia (C and D) and transversal section of lumbar spinal
cord (E-H) at the ipsi-lateral (E and F) or contra-lateral region (G and H). All samples were obtained from rats 10 days after treatment with BMMC.
Sciatic nerve and DRG sections were double immunolabeled for GFAP/FGF-2 (A and C) and NF-200/FGF-2 (B and D). LSC sections were double
immunolabeled for GFAP/FGF-2 and Tuj-1/FGF-2. White arrows indicate yellow areas of colocalisation between glial marker (GFAP) and FGF-2 and
neuronal markers (NF-200/Tuj-1) and FGF-2. Scale bar: A-H = 50 μm.
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Figure 5 Increased expression of FGF-2 is time correlated with increased satellite cell proliferation in the DRG after nerve lesion and
BMMC treatment. A-D; F-I: Longitudinal sections of dorsal root ganglia (DRG) of adult rats. A: Low magnification photomicrograph of a
longitudinal section of an uninjured DRG stained with neutral red. Insert show neurons in different cell size (low, medium and big size). B-D:
Optical sections of DRGs slices by confocal microscopy taken 10 days after total transection immunolabeled for FGF-2 (red) and counterstained
with TO-PRO (blue) treated with PBS (C) or BMMC (D) or uninjured sciatic nerve (B). E: Quantification of the fluorescence intensity compared
between the experimental groups cited above. Statistics: p<0,0001 ANOVA. F-I: Optical.
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sal section of LSC with an anti-GFAP and anti-FGF-2
antibodies or with anti-NF-200 and anti-FGF-2 anti-
bodies. At the ipsi-lateral region both motoneurons and
astrocytes express FGF-2 (Figure 4E and F) and similar
results were observed at the contra-lateral side(Figure 4G and H). In conclusion, cell treatment
increased FGF-2 expression and astrocyte proliferation
on the injured size of the spinal cord in the ventral horn
where the motoneuron cell bodies that form the sciatic
nerve are located. Blocking FGF-2 with aneutralizing
antibody reduced astrocyte proliferation, suggesting that
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marrow derived cells.
FGF-2 neutralization reduces SC survival and proliferation
in vitro
Low-density cultures of human SC line treated with CM
derived from bone marrom cells had 20% more proliferat-
ing SCs after 48 h compared to the control group
(Figure 7A, B and F, Additional file 3: Figure S3). Addition
of the neutralizing FGF-2 antibody reduced the number of
proliferating SCs in both low- and high-density cultures
(30% and 15% respectively, Figure 7C and F, Additional file
3: Figure S3). Recombinant human FGF-2 protein (rhFGF-
2) increased cell proliferation (Figure 7D and F), but in the
presence of neutralizing FGF-2 antibody, cultures treated
with rhFGF-2 had cell proliferation levels similar to that of
the control (Figure 7E and F, Additional file 3: Figure S3).
Conditioned medium of BMC in the presence of small
pieces of injured sciatic nerve also increased SC prolifera-
tion at the same levels compared to the CM in the absence
of nerve pieces (Figure 7F). Neutralizing FGF-2 antibody
added to the CM of BMC in the presence of nerve pieces
reduced in 38% the number of KI-67+ SC (Figure 7F).
Mouse IgG was used as immunoglobulin control and did
not alter SC proliferation when added to the control or CM
(Figure 7F).
We analyzed the effect of neutralization of FGF-2 on the
activation of phosphorylated Akt (p-Akt, Figure 7G) and
extracellular signal-related kinase (p-ERK 1/2, Figure 4H),
as these pathways are related to survival and proliferation
of SCs. Addition of CM increased Akt and ERK phosphor-
ylation (14% and 25% respectively, Figure 7G-H) when
compared to the control group. Addition of the neutralizing
FGF-2 antibody to the CM reduced the phosphorylation of
Akt and ERK 1/2 compared to the CM-only group (42%
and 18%,respectively). Treatment with rhFGF-2 increased
Akt phosphorylation (Figure 7G, p< 0.01) but had no effect
on ERK 1/2 (Figure 7H, p> 0.01), compared to the control
(DMEM) group. This suggests that bone marrow-derived
FGF-2 is an important trophic factor that affects the sur-
vival and proliferation of SCs. Because basal levels of phos-
phorylation are seen following FGF-2 neutralization, it is
possible that other unidentified soluble factor(s) present in
the CM also affect SC survival and proliferation.
We also analyzed the levels of FGF-2 RNA in the mono-
nuclear fraction of BMMC and the adherent fraction of
MSC cultured with or without small pieces of injured sci-
atic nerve (Figure 7I). Quantitative analysis showed that in
MSC, the presence of the sciatic nerve increased 7-fold
the amount of FGF-2 transcripts (p< 0,0001). However,
BMMC cultured with small pieces of injured sciatic nerve
decreased the transcript level a fold (p< 0,0001). This sug-
gests that mesenchymal cells, which represents about
0,01% of BMMC [18], in contact with lesioned sciaticnerve overexpress FGF-2, a result that had previously been
observed in the sciatic nerve tissue of rats treated with
BMMC.Bone marrow-derived FGF-2 stimulates SC migration after
nerve lesion
SCs in the presence of degenerating axons after peripheral
nerve injury proliferate and migrate to form a permissive
microenvironment for axonal regeneration [1]. We tested
the potential of CM to induce SC migration in rat sciatic
nerve explants cultured for 24 h after nerve crush. Migrat-
ing Schwann cells (S100-β+) were quantified and com-
pared between experimental groups as described
previously with the use of a square grid (Figure 3A). CM
increased the number of migrating S100-β+SCs by 32%
compared to the control condition (Figure 3B, C and G).
Addition of neutralizing FGF-2 to the CM attenuated the
increase by 48% (Figure 3, D and G). Addition of rhFGF-2
to the culture medium had an effect similar to the CM,
and the neutralization of FGF-2 blocked this positive effect
(Figure 3E, F, G). One might argue that fibroblasts and
endothelial cells also migrate from the sciatic nerve
explants in culture, but these cells do not express S100-β
and only their cell nuclei are visible, preventing false posi-
tives in our data (Figure 3B, thin and thick arrows). More-
over, the total number of migrating cells (SC and non-SCs)
is also reduced when FGF-2 is neutralized in the CM
(Additional file 4: Figure S4). These results suggest that
FGF-2 derived from BMMC has an important role in SC
migration following nerve injury.Neutralization of FGF-2 reduces neurite outgrowth of
DRG neurons induced by BMMC-CM
It is well-known that FGF-2 binds to FGFR-3 in DRG
neurons and that activation of this receptor promotes
neuronal survival and axonal growth [10]. To confirm
the presence of FGF-2 in the CM, dissociated DRG neu-
rons were cultured under the same experimental condi-
tions as described above for SCs. DRG neurons
incubated with CM (Figure 8B, G) exhibited extensive
neurite outgrowth 48 h after plating (4-fold increase)
compared to the control group (Figure 8A, G). The
neutralization of FGF-2 reduced neurite outgrowth to
basal levels (Figure 8C), while addition of rhFGF-2
(20 ng/mL) to the medium also increased neurite out-
growth, but not to the levels elicited by CM (Figure 8D,
G). Addition of both FGF-2 and nerve growth factor
(NGF, 20 ng/mL) to control medium induced a strong
neurite outgrowth similar to the neurons incubated with
CM (Figure 8F-G). Altogether, our data provide strong
evidence that FGF-2 is secreted by BMMC. Moreover,
this FGF-2 promotes glial survival and proliferation and
neurite outgrowth of rat DRG neurons.
Figure 6 Increased expression of FGF-2 is time correlated with increased astrocyte proliferation in the LSC after nerve lesion and
treatment with BMMC. A: Low magnification photomicrogragh of lumbar spinal cord with an uninjured sciatic nerve stained with neutral red.
The DL region is circled. B-F: Optical sections by confocal microscopy of LSC at DL region immunolabeled for FGF-2 ten days after sciatic nerve
lesion treated with PBS (B, ipsi-lateral and C, contralateral) or BMMC (E, ipsi-lateral and F, contralateral). D: LSC section of an uninjured rat. Cell
nuclei were counterstained with TO-PRO G: histogram of FGF-2 fluorescence between experimental groups. Statistics: p<0.001 ANOVA. H-N:
Optical slides by confocal microscopy of the DL region of LSC double immunolabeled for KI-67 (red) and GFAP (green) ten days after sciatic
nerve lesion treated with PBS (H, ipsi-lateral and K, contralateral), BMMC (I, ipsilateral and L, contralateral) or BMMC+ neutralizing FGF-2 antibody
(J, ipsilateral and M, contralateral) delivered by osmotic mini-pumps. N: LSC section of an uninjured rat. O: Histogram of the number of KI-67/
GFAP + astrocytes at DL/LSC region per mm2. Statistics: p<0.001 ANOVA. Scale bars: A = 200 μm; B-F, H-M=50 μm.
Ribeiro-Resende et al. Molecular Neurodegeneration 2012, 7:34 Page 12 of 17
http://www.molecularneurodegeneration.com/content/7/1/34Discussion
Trophic activity derived from BMMC is a fundamental
issue in the stem cell field and the identication of neuro
and glial factors expressed in small amounts might beuseful to therapies on regeneration. Several mechanisms
have been suggested to explain how BMMC contribute
to improve cell therapy following nerve injury
[1,5,15,19,20]. Initial observations suggested that bone
Figure 7 Neutralizing FGF-2 antibody blocks SC proliferation and survival induced by BMMC-CM in vitro. A-E: ST-8814 SCs cultured for
48 h in low density (2.00 x 104 cells/well) with DMEM F-12 + 10% FBS (A), CM (B), CM+ neutralizing FGF-2 antibody (C), rhFGF-2 (D) or rhFGF-2 +
neutralizing FGF-2 antibody (E). Cells were immunolabeled for KI-67 and cell nuclei were counterstained with DAPI. F: Quantification of the
percentage of KI-67+ SC per mm2. Statistics: p<0.0001 ANOVA. G and H: Western blotting and quantitative analysis of the active Akt (p-Akt, G)
and active ERK 1/2 (p-ERK 1/2, H) from SCs cultured for 48 h with control medium, CM, CM+ neutralizing FGF-2, rhFGF-2 + neutralizing FGF-2 or
rhFGF-2. I: Semi quantitative polymerase chain reaction (RT-PCR) for FGF-2 transcripts from samples of BMMC or MSC in the presence or absence
of sciatic nerve pieces. Quantitative analysis showing the transcript level following the same experimental conditions. Statistics: p<0.0001 ANOVA.
Scale bar: A-E=50 μm.
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any neural cell type depending on the environment
conditions [21-24]. However, the number of presumed
differentiated cells could not explain some of the
improvements observed in the experimental rodentmodels. Recently, several molecules secreted from
BMMC including nerve growth factor (NGF), brain
derived neurotrophic factor (BDNF), cilliary neuro-
trophic factor (CNTF), vascular endothelial growth
factor (VEGF), transforming growth factor β1 (TGF-β1)
Figure 8 FGF-2 secreted by BMMC stimulates neuritogenesis of DRG neurons co-cultured with SC. A-F: Optical sections obtained by
confocal microscopy of E16 rat embryo DRG sensory neurons (Tuj-1, red) and SCs (GFAP, green) incubated for 48 h with DMEM F-12 (control
medium, A), bone marrow conditioned medium (CM, B), CM+neutralizing FGF-2 antibody (C), rhFGF-2 added to the control medium (D),
rhFGF-2 + neutralizing FGF-2 antibody (E) or rhFGF-2 + rhNGF (F). Both cell types derived from cultured DRG explants of E16 rat embryos. Cell
nuclei were counterstained with TO-PRO. All culture media were serum-free. rh: recombinant human protein. G: Quantification of the average
neurite length per neuron under the experimental conditions described above. Statistics: p< 0.001. Scale bars: A-F = 50 μm.
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didates that support cell therapy [25-28]. These soluble
factors activate specific receptors to induce survival,
growth, proliferation, migration and differentiation of
specific cell types such as neural precursors, neurons,
glial cells and vascular cells [1,3,29-31].In our previous work, we demonstrated that bone
marrow-derived soluble factors contribute to sciatic
nerve regeneration by promoting neuronal survival,
axonal growth and glial cell proliferation [5], including
SCs from the proximal stump of the transected nerve,
satellite cells of DRG and astrocytes surrounding
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a trophic factor produced and secreted by BMC because
its neutralization dramatically reduced the neuritogen-
esis of DRG neurons induced by BMC-CM. FGF-2 has
also been well characterized as a mitogen for glial cells
during the development and regeneration of the central
nervous system (CNS) and PNS [10]. Moreover, the sur-
vival of peripheral glial cells and their progression
through the cell cycle occurs through the activation of
FGFR 1/2.
It is widely known that activation of PI-3 kinase
(PI3K)/Akt leads to cell survival, whereas mitogen-
activated protein kinase (MAPK) activation induces cell
proliferation [10]. In addition, DRG neurons express
FGFR-3, which is activated by FGF-2, promoting neur-
onal survival and neuritogenesis by PI3K and MAPK sig-
naling pathways respectively, in vitro and in vivo [10,32].
Here, we demonstrate that BMC-CM induces survival
and proliferation of SCs and neuritogenesis of DRG neu-
rons (Figure 6). The neutralization of FGF-2 reduced the
positive effects previously observed in both cell types.
Addition of rhFGF-2 to culture medium promoted simi-
lar effects, but these effects were not as strong as those
observed in SCs or neurons incubated with CM. This
suggests that other possible unidentified soluble factor(s)
secreted by BMC might also affect cell survival, prolif-
eration and neuritogenesis (Figure 7F-H; Figure 8). In-
deed, this hypothesis is supported by the fact that NGF
is one of these factors [5]. Another point observed was
that when FGF-2 activity was blocked in the CM the
neurite growth was almost blocked as well (Figure 8G).
Since NGF was found in the CM, would be expected
to observe strong neurite growth after FGF-2
neutralization. However, it was reported that when the
activity of FGF receptor is blocked, MAP kinase signal-
ing pathway triggered by NGF is severely committed
[33].
Here, we provide strong evidence that BMC express
and release FGF-2. Injection of BMC inside the hollow
tube containing the proximal and distal nerve stumps
supplies additional FGF-2 during the early period of
regeneration. This might increase the SC proliferation
rate. However, increased proliferation of satellite cells
surrounding sensory DRG neurons and astrocytes
close to the motoneurons in LSC was also observed
(Figures 2, 5, 6).
It is well established that soluble molecules such as
trophic factors (e.g., NGF, BDNF, NT-3 and FGF-2) are
transported along axons in both anterograde and retro-
grade directions [3,34,35]. Therefore, it is tempting to
speculate that FGF-2 secreted by BMC at the lesion site
could be transported to DRGs and LSC via axonal trans-
port. Moreover, absence of electrical signaling leads
to apoptosis of injured DRG neurons and shrunkenmotoneurons in the CNS [36]. BMC treatment induces
FGF-2 overexpression in both DRG (Figure 5) and LSC
(Figure 6). It is possible that glial proliferation is stimu-
lated by FGF-2 from multiple sources such as BMMC
that activates neuronal cell bodies by axonal transport
and by autocrine release by neurons and glial cells.
Neutralization of FGF-2 concomitantly with BMC treat-
ment at the lesion site reduced FGF-2 expression in
DRG and LSC tissue (data not shown). This observa-
tion supports the hypothesis that bone marrow-derived
FGF-2 stimulates local FGF-2 expression by DRG and
LSC, as well as the axonal transport of this factor to
the neuronal cell bodies. BMC treatment also leads to
an increased in the proliferation of satellite cells and
astrocytes. Both cell types might be ensheathing and
contacting sensory and motor neurons with transected
axons. Because glial cells provide trophic support to
neurons [37], an increased number of these cells would
lead to an increase in trophic factors. This explanation
can be supported by our previous observation that
BMC treatment enhances glial cell proliferation and
neuronal survival [5]. Interestingly, increased levels of
FGF-2 with bone marrow cells therapy have also been
reported in regenerating tissue in a model of optic
nerve crush lesions [15].
FGF-2 is a mitogenic factor for SCs and can also in-
duce migration of glial cells in vitro which includes
SC. Data from in vitro sciatic nerve explants showed
that FGF-2 neutralizing antibody added to the CM
reduces SC migration (Figure 3). However, the total
number of migrating cells significantly decreased under
this experimental condition. It is known that endothe-
lial cells and fibroblasts also migrate from the explants,
but the numbers of these migrating cells were not altered
(data not shown). Therefore, we suggest that the effect of
soluble FGF-2 in the CM is mainly on SCs in migratory
experiments. Based on these results, we confirm that FGF-
2 neutralization reduces the migratory process in vitro and
we conclude that FGF-2 secreted by BMC regulates glial
cell proliferation and migration. These phenomena are im-
portant because the peripheral glial cells provide a suitable
environment for neuronal survival and axonal regeneration
after nerve lesion. Moreover, an increase in the number of
SC as well as in their migration could results in an increase
in nerve regeneration and functional improvements.
Finally, we show that the presence of regenerating nerve
tissue increases FGF-2 mRNA transcript levels using a
model of co-cultured sciatic nerve pieces and MSC. In the
absence of nerve fragments, BMMC or MSC had weak or
undetectable signals for FGF-2 mRNA by RT-PCR
(Figure 7I). These observations suggest an up-regulation of
FGF-2 expression by SCs and MSC since both cell types
stimulate each other to overexpress this trophic factor
(Figures 2 and 7). We demonstrated that FGF-2 is
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atic nerve were added to the culture of mesenchymal cells.
However, the amount FGF-2 transcripts is reduced in
BMMC when the same samples of nerve were added to
the culture. Since mesenchymal cells represent around
0,01% of bone marrow mononuclear cells [18], we suggest
that these cells are the main source of FGF-2. In autocrine
or paracrine loops involving trophic factors, it is well under-
stood that the first step toward overexpression of a factor is
to raise the amount of the receptor in the plasma mem-
brane [33]. The presence of more FGFRs at the cell surface
enhances the response to FGF-2. As described above for
SCs and MSCs, the same principle might apply to the inter-
action of DRG satellite cells and LSC astrocytes with MSCs.
Further studies are necessary to confirm this hypothesis.
In conclusion, this work clearly demonstrates that
bone marrow-derived FGF-2 contributes to peripheral
nerve regeneration by stimulating glial cell survival and
proliferation. Together with recent reports, this work
supports the hypothesis that different bone marrow-
derived molecules are working together during periph-
eral nerve regeneration leading to reduction of neuronal
death and increasing axonal growth. Consequently, these
events contribute for regeneration of nerve tissue and
functional recovery of the injured PNS.Additional files
Additional file 1: Figure S1. Optical slice of a longitudinal section of
sciatic nerve taken by confocal microscopy 10 days after injury and double
immunolabeled for Erb-B2 (green) and FGF-2 (red). Colocalization of both
markers is represented by yellow dots (arrows). Scale bar = 50 μm.
Additional file 2: Figure S2. Quantitative analysis of GFAP reactivity in
the DL LSC after sciatic nerve transection and treatment with PBS, BMMC, or
BMMC+neutralizing FGF-2 antibody. Ipsi and contra-lateral sides to the
nerve lesion were quantified. Statistics: p< 0.001 ANOVA.
Additional file 3: Figure S3. Quantitative analysis of the number of
KI-67 + SCs cultured at high density (5.00 x 104) and incubated with DMEM
F-12 (control medium), BMMC-CM, BMMC-CM+neutralizing FGF-2
antibody, rhFGF-2 added to the control medium or rhFGF-2 +neutralizing
FGF-2 added to the standard medium. Statistics: p< 0.0001 ANOVA.
Additional file 4: Figure S4. Quantitative analysis of the number of
migrated cells from explants of crushed sciatic nerve of adult rats under
the same conditions as described in Figure 6F. Statistics: p< 0.001 ANOVA.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
VTRR contributed to the general administration, generation of in vivo
experimental model, histology procedures, cell culturing, fluorescence
imaging, interpretation of experimental results, and development and
writing of the manuscript. ACR performed cell culturing, generation of in vivo
experimental model, histology procedures, fluorescent imaging, statistical
analysis and manuscript writing. RMRL performed Schwann cell culture,
biochemistry assays of western blotting and quantitative analysis by
densitometry. RAMR establishing culture of neuronal and glial cell from DRG
samples and writing of manuscript. RMO writing of manuscript and direction
of the project. All authors read and approved the manuscript.Acknowledgments
We would like to thank Suelen Soares Sério and Felipe Marins for their
excellent technical assistance in the laboratory, Camila Zaverucha-do-Valle
and Louise Mesentier-Louro for the scientific support. This work was
supported by grants from Fundação de Amparo a Pesquisa do Estado do Rio
de Janeiro (FAPERJ), Conselho Nacional de Apoio à Pesquisa (CNPq) and
Coordenação e Aperfeiçoamente de Pessoal de Nível Superior (Capes).
Author details
1Laboratório de Neurobiologia Celular e Molecular, Programa de Terapia
Celular e Bioengenharia, Instituto de Biofísica Carlos Chagas Filho, UFRJ,
Centro de Ciências da Saúde, Bl. G, Cidade Universitária, 21949-900 Rio de
Janeiro, Brazil. 2Instituto Nacional de Ciência e Tecnologia de Biologia
Estrutural e Bioimagem - INBEB, Universidade Federal do Rio de Janeiro, Rio
de Janeiro, Brazil. 3Laboratório de Microbiologia Celular, Pavilhão de
Hanseníase, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro
21045-900, Brazil. 4Laboratório de Neuroquímica, Programa de Neurobiologia,
Instituto de Biofísica Carlos Chagas Filho, UFRJ, Centro de Ciências da Saúde,
Bl. C, Cidade Universitária, 21949-900 Rio de Janeiro, Brazil.
Received: 16 January 2012 Accepted: 1 May 2012
Published: 13 July 2012
References
1. Chen ZL, Yu WM, Strickland S: Peripheral Regeneration. Annu Rev Neurosci
2007, 30:209–233.
2. Jessen KR, Mirsky R: Schwann cells and their precursors emerge as major
regulators of nerve development. Trends Neurosci 1999, 22:402–410.
3. Goldberg JL, Barres BA: The relationship between neuronal survival and
regeneration. Annu Rev Neurosci 2000, 23:579–612.
4. Vargas ME, Barres BA: Why is Wallerian degeneration in the CNS so slow?
Annu Rev Neurosci 2007, 30:153–179.
5. Ribeiro-Resende VT, Pimentel-Coelho PM, Mesentier-Louro LA, Mendez RM,
Mello-Silva JP, Cabral-da-Silva MC, de Mello FG, de Melo Reis RA, Mendez-
Otero R: Trophic activity derived from bone marrow mononuclear cells
increases peripheral nerve regeneration by acting on both neuronal and
glial cell populations. Neuroscience 2009, 159:540–549.
6. Martinelli C, Sartori P, De Palo S, Ledda M, Pannese E: Increase in number
of the gap junctions between satellite neuroglial cells during lifetime: an
ultrastructural study in rabbit spinal ganglia from youth to extremely
advanced age. Brain Res Bull 2005, 67:19–23.
7. Huang TY, Cherkas PS, Rosenthal DW, Hanani M: Dye coupling among
satellite glial cells in mammalian dorsal root ganglia. Brain Res 2005,
1036:42–49.
8. Pannese E, Ledda M, Cherkas PS, Huang TY, Hanani M: Satellite cell
reactions to axon injury of sensory ganglion neurons: increase in
number of gap junctions and formation of bridges connecting
previously separate perineuronal sheaths. Anat Embryol (Berl) 2003,
206:337–347.
9. Thippeswamy T, McKay JS, Morris R, Quinn J, Wong LF, Murphy D:
Glial-mediated neuroprotection: evidence for the protective role of the
NO-cGMP pathway via neuron-glial communication in the peripheral
nervous system. GLIA 2005, 49:197–210.
10. Grothe C, Haastert K, Jungnickel J: Physiological function and putative
therapeutic impact of the FGF-2 system in peripheral nerve
regeneration–lessons from in vivo studies in mice and rats. Brain Res Rev
2006, 51:293–299.
11. Jungnickel J, Claus P, Gransalke K, Timmer M, Grothe C: Targeted disruption
of the FGF-2 gene affects the response to peripheral nerve injury. Mol
Cell Neurosci 2004, 25:444–452.
12. Jungnickel J, Klutzny A, Guhr S, Meyer K, Grothe C: Regulation of neuronal
death and calcitonin gene-related peptide by fibroblast growth factor-2
and FGFR3 after peripheral nerve injury: evidence from mouse mutants.
Neuroscience 2005, 134:1343–1350.
13. Haastert K, Lipokatic E, Fischer M, Timmer M, Grothe C: Differentially
promoted peripheral nerve regeneration by grafted Schwann cells
over-expressing different FGF-2 isoforms. Neurobiol Dis 2006, 21:138–153.
14. Timmer M, Muller-Ostermeyer F, Kloth V, Winkler C, Grothe C, Nikkhah G:
Enhanced survival, reinnervation, and functional recovery of intrastriatal
dopamine grafts co-transplanted with Schwann cells overexpressing
high molecular weight FGF-2 isoforms. Exp Neurol 2004, 187:118–136.
Ribeiro-Resende et al. Molecular Neurodegeneration 2012, 7:34 Page 17 of 17
http://www.molecularneurodegeneration.com/content/7/1/3415. Zaverucha-do-Valle C, Gubert F, Bargas-Rega M, Coronel JL, Mesentier-Louro
LA, Mencalha A, Abdelhay E, Santiago MF, Mendez-Otero R: Bone marrow
mononuclear cells increase retinal ganglion cell survival and axon
regeneration in the adult rat. Cell Transplant 2010, 20:391–406.
16. Fidelis-de-Oliveira P, Werneck-de-Castro JPS, Pinho-Ribeiro V, Shalom BCM,
Nascimento-Silva JA, Souza RH Costa E, Cruz IS, Rangel RR, Goldenberg RCS,
Campos-de-Carvalho AC: Soluble factors from multipotent mesenchymal
stromal cells have antinecrotic effect on cardiomyocytes in vitro and
improve cardiac function in infarcted rat hearts. Cell Transplant 2012,
in press.
17. Reis RA, Da Silva MC Cabral, Santos NE Loureiro Dos, Bampton E, Taylor JS,
De Mello FG, Linden R: Sympathetic neuronal survival induced by retinal
trophic factors. J Neurobiol 2002, 50:13–23.
18. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD,
Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential
of adult human mesenchymal stem cells. Science 1999, 284:143–147.
19. Pereira Lopes FR, Frattini F, Marques SA, Almeida FM, de Moura Campos LC,
Langone F, Lora S, Borojevic R, Martinez AM: Transplantation of bone-
marrow-derived cells into a nerve guide resulted in transdiffe into
Schwann cells and effective regeneration of transected mouse sciatic
nerve. Micron 2010, 41:783–790.
20. Shyu WC, Liu DD, Lin SZ, Li WW, Su CY, Chang YC, Wang HJ, Wang HW,
Tsai CH, Li H: Implantation of olfactory ensheathing cells promotes
neuroplasticity in murine models of stroke. J Clin Invest 2008,
118:2482–2495.
21. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez
XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A,
Low WC, Largaespada DA, Verfaillie CM: Pluripotency of mesenchymal
stem cells derived from adult marrow. Nature 2002, 418:41–49.
22. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL: Little evidence for
developmental plasticity of adult hematopoietic stem cells. Science 2002,
297:2256–2259.
23. Terada N, Hamazaki T, Oka M, Hoki M, Mastalerz DM, Nakano Y, Meyer EM,
Morel L, Petersen BE, Scott EW: Bone marrow cells adopt the phenotype
of other cells by spontaneous cell fusion. Nature 2002, 416:542–545.
24. Wurmser AE, Gage FH: Stem cells: cell fusion causes confusion. Nature
2002, 416:485–487.
25. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE,
Kolbeck R, Hoppe E, Oropeza-Wekerle RL, Bartke I, Stadelmann C, Lassmann
H, Wekerle H, Hohlfeld R: Activated human T cells, B cells, and monocytes
produce brain-derived neurotrophic factor in vitro and in inflammatory
brain lesions: a neuroprotective role of inflammation? J Exp Med 1999,
189:865–870.
26. Sieminski AL, Hebbel RP, Gooch KJ: Improved microvascular network
in vitro by human blood outgrowth endothelial cells relative to
vessel-derived endothelial cells. Tissue Eng 2005, 11:1332–1345.
27. Zassler B, Humpel C: Transplantation of NGF secreting primary
monocytes counteracts NMDA-induced cell death of rat cholinergic
neurons in vivo. Exp Neurol 2006, 198:391–400.
28. Tang J, Hua Y, Su J, Zhang P, Zhu X, Wu L, Niu Q, Xiao H, Ding X:
Expression of VEGF and neural repair after alprostadil treatment in a rat
model of sciatic nerve crush injury. Neurol India 2009, 57:387–394.
29. Fawcett JW, Keynes RJ: Peripheral nerve regeneration. Annu Rev Neurosci
1990, 13:43–60.
30. Schmidt CE, Leach JB: Neural tissue engineering: strategies for repair and
regeneration. Annu Rev Biomed Eng 2003, 5:293–347.
31. Ming GL, Song H: Adult neurogenesis in the mammalian central nervous
system. Annu Rev Neurosci 2005, 28:223–250.
32. Markus A, Patel TD, Snider WD: Neurotrophic factors and axonal growth.
Curr Opin Neurobiol 2002, 12:523–531.
33. Chevet E, Lemaître G, Janjic N, Barritault D, Bikfalvi A, Katinka MD: Fibroblast
growth factor receptors participate in the control of mitogen-activated
protein kinase activity during nerve growth factor-induced neuronal
differentiation of PC12 cells. J Biol Chem 1999, 274:20901–20908.
34. Lewin GR, Barde YA: Physiology of the neurotrophins. Annu Rev Neurosci
1996, 19:289–317.35. Liu RY, Snider WD: Different signaling pathways mediate regenerative
versus developmental sensory axon growth. J Neurosci 2001, 21:RC164.
36. Hara MR, Snyder SH: Cell signaling and neuronal death. Annu Rev
Pharmacol Toxicol 2007, 47:117–141.
37. Barres BA: The mystery and magic of glia: a perspective on their roles in
health and disease. Neuron 2008, 60:430–440.
doi:10.1186/1750-1326-7-34
Cite this article as: Ribeiro-Resende et al.: Bone marrow-derived
fibroblast growth factor-2 induces glial cell proliferation in the
regenerating peripheral nervous system. Molecular Neurodegeneration
2012 7:34.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
